Effects of treatment strategy on endothelial function

L. Tomasoni, S. Sitia, C. Borghi, A. F G Cicero, C. Ceconi, F. Cecaro, A. Morganti, V. De Gennaro Colonna, M. Guazzi, L. Morricone, A. E. Malavazos, P. Marino, C. Cavallino, Y. Shoenfeld, M. Turiel

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A large body of evidence indicates that endothelial dysfunction is a characteristic of patients with arterial hypertension. As functional abnormalities lead to impaired endothelium-dependent vasodilation, this early step of atherogenesis is potentially reversible.In addition to reducing blood pressure, the major families of anti-hypertensive drugs have a number of pleiotropic effects that could improve endothelial function. In particular, the renin-angiotensin system plays an important role in the pathogenesis of both arterial hypertension and endothelial dysfunction, and so drugs capable of limiting the dangerous effects of this hormonal axis, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers and renin inhibitors, could help prevent/delay/reverse the atherosclerotic process. New third-generation β-blockers and 5-phosphodiesterase inhibitors may affect endothelial function.Furthermore, the HMGCoA-reductase inhibitors currently used to reduce cholesterol levels have major pleiotropic anti-inflammatory and anti-hypertensive effects.The preservation or recovery of endothelial function in hypertensive patients is crucial to inhibit the development of atherosclerosis and the onset of cardiovascular events. This review focuses on the ancillary effects of hypertensive drugs and HMGCoA-reductase inhibitors that go beyond lowering blood pressure and cholesterol levels.

Original languageEnglish
Pages (from-to)840-844
Number of pages5
JournalAutoimmunity Reviews
Volume9
Issue number12
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Antihypertensive Agents
Atherosclerosis
Oxidoreductases
Cholesterol
Blood Pressure
Hypertension
Phosphodiesterase 5 Inhibitors
Angiotensin Receptor Antagonists
Recovery of Function
Renin-Angiotensin System
Angiotensin-Converting Enzyme Inhibitors
Renin
Vasodilation
Pharmaceutical Preparations
Endothelium
Anti-Inflammatory Agents
Therapeutics

Keywords

  • Antihypertensive drugs
  • Atherosclerosis
  • Autoimmunity disease
  • Endothelial dysfunction

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Tomasoni, L., Sitia, S., Borghi, C., Cicero, A. F. G., Ceconi, C., Cecaro, F., ... Turiel, M. (2010). Effects of treatment strategy on endothelial function. Autoimmunity Reviews, 9(12), 840-844. https://doi.org/10.1016/j.autrev.2010.07.017

Effects of treatment strategy on endothelial function. / Tomasoni, L.; Sitia, S.; Borghi, C.; Cicero, A. F G; Ceconi, C.; Cecaro, F.; Morganti, A.; De Gennaro Colonna, V.; Guazzi, M.; Morricone, L.; Malavazos, A. E.; Marino, P.; Cavallino, C.; Shoenfeld, Y.; Turiel, M.

In: Autoimmunity Reviews, Vol. 9, No. 12, 10.2010, p. 840-844.

Research output: Contribution to journalArticle

Tomasoni, L, Sitia, S, Borghi, C, Cicero, AFG, Ceconi, C, Cecaro, F, Morganti, A, De Gennaro Colonna, V, Guazzi, M, Morricone, L, Malavazos, AE, Marino, P, Cavallino, C, Shoenfeld, Y & Turiel, M 2010, 'Effects of treatment strategy on endothelial function', Autoimmunity Reviews, vol. 9, no. 12, pp. 840-844. https://doi.org/10.1016/j.autrev.2010.07.017
Tomasoni L, Sitia S, Borghi C, Cicero AFG, Ceconi C, Cecaro F et al. Effects of treatment strategy on endothelial function. Autoimmunity Reviews. 2010 Oct;9(12):840-844. https://doi.org/10.1016/j.autrev.2010.07.017
Tomasoni, L. ; Sitia, S. ; Borghi, C. ; Cicero, A. F G ; Ceconi, C. ; Cecaro, F. ; Morganti, A. ; De Gennaro Colonna, V. ; Guazzi, M. ; Morricone, L. ; Malavazos, A. E. ; Marino, P. ; Cavallino, C. ; Shoenfeld, Y. ; Turiel, M. / Effects of treatment strategy on endothelial function. In: Autoimmunity Reviews. 2010 ; Vol. 9, No. 12. pp. 840-844.
@article{2261743951c7491e98188864d7479ffd,
title = "Effects of treatment strategy on endothelial function",
abstract = "A large body of evidence indicates that endothelial dysfunction is a characteristic of patients with arterial hypertension. As functional abnormalities lead to impaired endothelium-dependent vasodilation, this early step of atherogenesis is potentially reversible.In addition to reducing blood pressure, the major families of anti-hypertensive drugs have a number of pleiotropic effects that could improve endothelial function. In particular, the renin-angiotensin system plays an important role in the pathogenesis of both arterial hypertension and endothelial dysfunction, and so drugs capable of limiting the dangerous effects of this hormonal axis, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers and renin inhibitors, could help prevent/delay/reverse the atherosclerotic process. New third-generation β-blockers and 5-phosphodiesterase inhibitors may affect endothelial function.Furthermore, the HMGCoA-reductase inhibitors currently used to reduce cholesterol levels have major pleiotropic anti-inflammatory and anti-hypertensive effects.The preservation or recovery of endothelial function in hypertensive patients is crucial to inhibit the development of atherosclerosis and the onset of cardiovascular events. This review focuses on the ancillary effects of hypertensive drugs and HMGCoA-reductase inhibitors that go beyond lowering blood pressure and cholesterol levels.",
keywords = "Antihypertensive drugs, Atherosclerosis, Autoimmunity disease, Endothelial dysfunction",
author = "L. Tomasoni and S. Sitia and C. Borghi and Cicero, {A. F G} and C. Ceconi and F. Cecaro and A. Morganti and {De Gennaro Colonna}, V. and M. Guazzi and L. Morricone and Malavazos, {A. E.} and P. Marino and C. Cavallino and Y. Shoenfeld and M. Turiel",
year = "2010",
month = "10",
doi = "10.1016/j.autrev.2010.07.017",
language = "English",
volume = "9",
pages = "840--844",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Effects of treatment strategy on endothelial function

AU - Tomasoni, L.

AU - Sitia, S.

AU - Borghi, C.

AU - Cicero, A. F G

AU - Ceconi, C.

AU - Cecaro, F.

AU - Morganti, A.

AU - De Gennaro Colonna, V.

AU - Guazzi, M.

AU - Morricone, L.

AU - Malavazos, A. E.

AU - Marino, P.

AU - Cavallino, C.

AU - Shoenfeld, Y.

AU - Turiel, M.

PY - 2010/10

Y1 - 2010/10

N2 - A large body of evidence indicates that endothelial dysfunction is a characteristic of patients with arterial hypertension. As functional abnormalities lead to impaired endothelium-dependent vasodilation, this early step of atherogenesis is potentially reversible.In addition to reducing blood pressure, the major families of anti-hypertensive drugs have a number of pleiotropic effects that could improve endothelial function. In particular, the renin-angiotensin system plays an important role in the pathogenesis of both arterial hypertension and endothelial dysfunction, and so drugs capable of limiting the dangerous effects of this hormonal axis, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers and renin inhibitors, could help prevent/delay/reverse the atherosclerotic process. New third-generation β-blockers and 5-phosphodiesterase inhibitors may affect endothelial function.Furthermore, the HMGCoA-reductase inhibitors currently used to reduce cholesterol levels have major pleiotropic anti-inflammatory and anti-hypertensive effects.The preservation or recovery of endothelial function in hypertensive patients is crucial to inhibit the development of atherosclerosis and the onset of cardiovascular events. This review focuses on the ancillary effects of hypertensive drugs and HMGCoA-reductase inhibitors that go beyond lowering blood pressure and cholesterol levels.

AB - A large body of evidence indicates that endothelial dysfunction is a characteristic of patients with arterial hypertension. As functional abnormalities lead to impaired endothelium-dependent vasodilation, this early step of atherogenesis is potentially reversible.In addition to reducing blood pressure, the major families of anti-hypertensive drugs have a number of pleiotropic effects that could improve endothelial function. In particular, the renin-angiotensin system plays an important role in the pathogenesis of both arterial hypertension and endothelial dysfunction, and so drugs capable of limiting the dangerous effects of this hormonal axis, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers and renin inhibitors, could help prevent/delay/reverse the atherosclerotic process. New third-generation β-blockers and 5-phosphodiesterase inhibitors may affect endothelial function.Furthermore, the HMGCoA-reductase inhibitors currently used to reduce cholesterol levels have major pleiotropic anti-inflammatory and anti-hypertensive effects.The preservation or recovery of endothelial function in hypertensive patients is crucial to inhibit the development of atherosclerosis and the onset of cardiovascular events. This review focuses on the ancillary effects of hypertensive drugs and HMGCoA-reductase inhibitors that go beyond lowering blood pressure and cholesterol levels.

KW - Antihypertensive drugs

KW - Atherosclerosis

KW - Autoimmunity disease

KW - Endothelial dysfunction

UR - http://www.scopus.com/inward/record.url?scp=77956903104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956903104&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2010.07.017

DO - 10.1016/j.autrev.2010.07.017

M3 - Article

VL - 9

SP - 840

EP - 844

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 12

ER -